No Data
No Data
Shenzhen Chipscreen Biosciences (688321.SH): The company was selected as one of the sixth batch of national specialized, special and new "little giant" enterprises.
On September 9, Guolong announced that Shenzhen Chipscreen Biosciences (688321.SH) recently, according to the official announcement of the sixth batch of specialized, special and new 'little giant' enterprises and the third batch of specialized, special and new 'little giant' enterprises in Shenzhen by the Small and Medium Enterprise Service Bureau of Shenzhen, Shenzhen Chipscreen Biosciences Co., Ltd. has been selected for the national 'sixth batch of specialized, special and new 'little giant' enterprise publicity list', and the publicity period for the selected list has ended.
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) P/S Is On The Mark
Shenzhen Chipscreen Biosciences (688321.SH): Has reserves of research and development projects related to monkeypox.
Shenzhen Chipscreen Biosciences, listed on the Shanghai Stock Exchange, stated on the investor interaction platform on August 16th that the company has reserved research and development projects related to monkeypox, and the CDCS23 project has completed some preclinical work and has excellent antiviral activity.
Half-year report for the year 2024.
Summary of Half-Year Report in 2024.
Shenzhen Chipscreen Biosciences (688321.SH): net loss of 410.064 million yuan in the first half of the year.
On August 15th, Chipscreen Biosciences (stock code: 688321.SH) announced that it achieved revenue of 0.302 billion yuan during the reporting period, a year-on-year increase of 25.06%; the net income attributable to shareholders of the listed company was -41.0064 million yuan. The revenue increased by 25.06% compared to the same period last year, mainly due to the 11.74% year-on-year growth in sales of Sida Benamine, with revenue increasing by 4.15% (due to a 6% reduction in medical insurance price); sales of Seglitide Sodium increased by 396.15% year-on-year, and revenue increased by 632.48% year-on-year; the net income attributable to shareholders of the listed company decreased by -126 compared with the same period last year.
No Data